The lifetime risk of major depressive disorder is 20-25% for women and 7-12% for men 1 . Despite several decades of intense research, our understanding of the pathophysiology of this disease is limited. Treatments remain inadequate and, when effective, delayed in their onset and afflicted with side effects 1 . Thus, there is a major unmet medical need for more effective therapies. To that end, a better understanding of the pathogenesis of major depressive disorder, as well as of the actions of antidepressants, is needed. The most commonly used class of antidepressants is the selective serotonin (5-hydroxytryptamine (5-HT)) reuptake inhibitors (SSRIs), which, by increasing extracellular levels of 5-HT, activate multiple pre-and postsynaptic 5-HT receptors (5-HTRs). In an effort to find endogenous modulators of 5-HTR function, we searched for interacting partners of distinct 5-HTRs using a yeast two-hybrid screen 2 . These experiments showed that 5-HTR 1B (5-HT 1B R), 5-HT 1D R and 5-HT 4 R all interacted with a protein known as p11 (also known as S100A10, nerve growth factor-induced protein 42C, calpactin I light chain and annexin II light chain) 2, 3 . Studies of transfected cell lines showed that overexpression of p11 increased the levels of 5-HT 1B R and 5-HT 4 R at the cell surface, resulting in enhanced effects of these receptors on cell signalling 2, 3 . This indicated that p11, like SSRIs, potentiates 5-HT neurotransmission.
p11 is a member of the S100 EF-hand protein family. S100 proteins are small acidic proteins (10) (11) (12) and constitute the largest subfamily of EF-hand proteins, which has at least 25 members 4 . S100 proteins exist as symmetrical homo-and heterodimers, and each monomer contains two EF-hand motifs that bind calcium. A unique feature of p11 is that it contains mutations in both of the calcium-binding sites, making it insensitive to calcium. p11 was initially identified within a heterotetrameric complex that it forms with annexin A2 (REF. 5 ). Prior studies also showed that p11 interacts with ion channels (including sodium channel protein type 10α (also known as Na V 1.8), potassium channel subfamily K, acid-sensing ion channels, transient receptor potential cation channel subfamily V member 5) and enzymes, such as tissue plasminogen activator and phospholipase A2 (REFS 6, 7) .
Immunohistochemistry and in situ hybridization studies in mouse and human brains revealed that p11 is expressed in GABAergic and cholinergic interneurons and in monoaminergic, cholinergic, glutamatergic and GABAergic projection neurons 2, 3, 8, 9 . p11 is not restricted to neurons; it is also found in, for example, epithelial and endothelial cells 7 . Interestingly, p11 is expressed in several brain regions that are implicated in the pathophysiology of depression, including the nucleus accumbens (FIG. 1a,b ), cerebral cortex (FIG. 1c,d ) and hippocampus 8, 10, 11 (FIG. 1e-g ). These results prompted us to evaluate the possibility that altered p11 levels or functioning underlie aspects of depression-like states and that p11 regulates responses to antidepressants.
Of clinical and translational relevance, p11 mRNA and protein levels are downregulated in the anterior cingulate cortex and the ventral striatum (specifically, the nucleus accumbens) from depressed individuals 2, 12 and in H/Rouen mice (which display a helpless phenotype in the tail suspension test and are therefore used as a genetic animal model of depression 2 ). Studies in suicide victims have also found reductions of P11 mRNA levels in the hippocampus and amygdala, suggesting an important role of p11 in multiple regions implicated in depression pathophysiology 13 . Conversely, antidepressants of several distinct categories -SSRIs, tricyclic antidepressants and monoamine oxidase inhibitors -as well as electroconvulsive treatment, increase p11 expression in the frontal cortex and hippocampus of mice and rats 2, 14 . Here, we review the current state of knowledge of the regulation of p11 expression. We also summarize the behavioural phenotypes in constitutive and conditional p11-knockout mice and in mice with virusmediated knockdown or overexpression of p11. Finally, we review mechanisms of p11 action, with an emphasis on its interaction with 5-HTRs, annexin A2 and SWI/SNFrelated matrix-associated actin-dependent regulator of chromatin subfamily A member 3 (SMARCA3: also known as HLTF), as well as its potential role in depression and in mediating therapeutic responses to antidepressants. Abstract | Studies of the multifunctional protein p11 (also known as S100A10) are shedding light on the molecular and cellular mechanisms underlying depression. Here, we review data implicating p11 in both the amplification of serotonergic signalling and the regulation of gene transcription. We summarize studies demonstrating that levels of p11 are regulated in depression and by antidepressant regimens and, conversely, that p11 regulates depression-like behaviours and/or responses to antidepressants. Current and future studies of p11 may provide a molecular and cellular framework for the development of novel antidepressant therapies. Regulation of p11 levels Neurotransmitters and growth factors. Chronic treatment with any of the several antidepressants that exert their therapeutic actions by increasing extrasynaptic concentrations of monoamines increases p11 mRNA levels in the cortex and hippocampus of mice 2, 14 . In addition to monoamine-based antidepressants, treatment with the dopamine precursor l-3,4-dihydroxyphenylalanine (l-DOPA) increases p11 mRNA and protein levels 15 . The mechanisms underlying the monoamine-regulated increase in p11 levels need to be more thoroughly characterized, but they appear to involve an upregulation of brain-derived neurotrophic factor (BDNF) signalling 14 . Accordingly, antidepressant regimens regulate the levels of BDNF in the cortex and hippocampus 16 . Studies using neuronal cultures and mutant mice overexpressing BDNF have provided evidence that signalling through the receptor tyrosine kinase TRKB (also known as NTRK2) and extracellular signal-regulated kinase (ERK; also known as MAPK)-mediated signalling pathway appears to mediate the induction of p11 by this neurotrophin 14 . Conversely, p11 mRNA and protein levels are reduced in the striatum and cortex from BDNF-knockout mice 14 . In addition, 5-HT induces p11 more potently in neuronal cultures from wildtype mice than those from BDNF-knockout mice 14 . These findings suggest that effects of neurotransmitters on p11 levels may, at least in part, be mediated by changes in BDNF signalling (FIG. 2a) . It is likely that additional growth factors regulate p11 levels in neurons. It has been shown, for example, that nerve growth factor potently stimulates p11 expression in dorsal root ganglia in vivo 17 and in PC12 cells in vitro 18 .
Cytokines and glucocorticoids.
Intraperitoneal injections of cytokines, including interferon-γ and tumour necrosis factor-α, increase p11 protein levels in the mouse frontal cortex 19 . Subchronic administration of another cytokine, interleukin-1β, in a regimen that induces sickness behaviour, also increases p11 mRNA levels in the mouse prefrontal cortex and hippocampus 20 . Using p11 as a molecular readout for antidepressant responses and noting its regulation by cytokines, we found that anti-inflammatory drugs reduce the efficacy of SSRIs in rodents and humans. In mice, when anti-inflammatory drugs are chronically co-administered with an SSRI, p11 levels are not increased and the behavioural response to the SSRI is blocked (FIG. 2b) , whereas anti-inflammatory drugs alone have no effect on depressionrelated behaviours 19 . Although cytokines appear to be potent regulators of p11, it
is not yet clear whether they increase p11 production directly via cytokine receptorinduced signalling pathways or act indirectly -for example, by affecting the production and signalling of neurotrophic factors, such as BDNF.
The apparent contradictions between the studies showing cytokine regulation of p11 and the clinical literature showing an association between increased cytokine levels and depression 21 have several possible explanations that will require further experimental investigation. First, clinical studies have shown that peripheral administration of certain cytokines (interferon-α) and increased inflammation cause depression symptoms in humans 21 . The specific cytokines (and cell types from which they are released) that increase p11 have not been fully characterized, especially in humans. It is possible that the cytokines mediating depression symptoms in humans are distinct from those that mediate the rise in p11 levels in the brain. If the same cytokines are involved in both processes, the discrepancy may be due to differences in the local concentration of the cytokine: there is evidence that, depending on the dose and duration of cytokine delivery, a given cytokine (such as interleukin-1β) either increases or decreases levels of neurotrophins and can thereby have both trophic and toxic effects on downstream target cells 22 . Second, there is a clinical literature supporting the use of anti-inflammatory agents to augment the efficacy of noradrenaline reuptake inhibitor-type antidepressants 23 , whereas our studies in mice and humans demonstrate that anti-inflammatory drugs antagonize the efficacy of SSRIs. In fact, analysis of the COMED clinical trial has indicated that concomitant non-steroidal anti-inflammatory drug (NSAID) use reduces the efficacy of SSRIs while augmenting the response to other classes of antidepressant drugs 24 . It is therefore important to emphasize the specificity of the antagonism between anti-inflammatory agents and the SSRI class of antidepressants. It may turn out that this antagonism may be overcome by increasing the dose of SSRIs or by taking advantage of the other available antidepressant drug options.
In addition, one study has shown that exposure to inescapable footshock stress or administration of the synthetic glucocorticoid dexamethasone increases p11 mRNA levels in the prefrontal cortex by activating glucocorticoid response elements in the p11 promoter 25 . Considering the depressionlike phenotype of p11-knockout mice, the expectation would be that stress, a factor that can precipitate or worsen depression, would lower p11 levels. The observed increase in p11 levels in response to stress or glucocorticoid exposure could be a compensatory physiological response to counteract depression symptoms by raising p11 levels and thus sensitivity to 5-HT.
The above-mentioned data indicate that p11 is regulated by BDNF, cytokines and glucocorticoids -factors that are critically implicated in mood regulation. However, more detailed studies are required to understand the role of the paradoxical induction of p11 by stress and pro-inflammatory cytokines and to formulate a coherent molecular model of the interaction of p11 with these factors in depression and antidepressant actions.
Behaviours in p11 mouse models Studies in mice lacking p11 have shown that p11 has a crucial role in regulating depression-like behaviours and responses to SSRIs and tricyclic antidepressants. Constitutive p11-knockout mice, which lack p11 throughout the brain and body, show a depression-like behavioural HT) ) reuptake inhibitor (SSRI)-type antidepressants increase brain-derived neurotrophic factor (BDNF)-receptor tyrosine kinase TRKB-mediated regulation of p11, which subsequently stimulates hippocampal neurogenesis and induces behavioural improvement. b | SSRI-type antidepressants increase levels of certain cytokines in the brain, which in turn increase levels of p11, the effect of which produces behavioural antidepressant responses. This pathway can be antagonized by co-administration of non-steroidal anti-inflammatory drugs (NSAIDs).
phenotype in several well-established tests that measure behavioural despair (for example, forced swim and tail suspension tests) or anhedonia (for example, sucrose preference test) 2, 14 . p11-knockout mice also show a deficit in emotional learning, as indicated by impaired performance in the passive avoidance task 26 . In addition to the observed depressive-like phenotype in these tests, constitutive p11-knockout mice show reduced responses to antidepressant administration in the forced swim, tail suspension and novelty-suppressed feeding tests 2, 14, 27 . Together, these behavioural studies indicate that constitutive loss of p11 is sufficient to induce a depression-like state and that p11 is crucial for antidepressant responsiveness.
The nucleus accumbens has been identified as a critical region for the depressionlike behaviour in p11-knockout mice 8, 12 . Specifically, reducing p11 expression only in the nucleus accumbens by virus-mediated RNAi was sufficient to recapitulate the depressive-like behavioural phenotype observed in the constitutive p11-knockout mice 12 . In wild-type mice, p11 is enriched 30-fold in accumbal cholinergic interneurons compared with neighbouring celltypes 8 (FIG. 1a,b) , and removal of p11 from these cholinergic neurons caused a depressive-like behavioural phenotype 8 . Conversely, virus-mediated overexpression of p11 in accumbal cholinergic interneurons, but not in those of the dorsal striatum, was sufficient to reverse the depression-like phenotype of constitutive p11-knockout mice 8 . Interestingly, removal of accumbal p11 did not reduce the effect of SSRIs on immobility in the tail suspension test 8, 12 . Thus, although accumbal p11 seems to be crucial in the regulation of mood-related behaviours, it does not seem to mediate antidepressant responses. Instead, cortical expression of p11 appears to be required for responses to antidepressants in rodent behavioural models. Chronic antidepressant treatment increased p11 levels in the cortex and hippocampus 2, 10, 14 , and increased Htr4 (which encodes 5-HT 4 R) mRNA levels in p11-containing cortical neurons in mice 10 . Removal of p11 from pyramidal projection neurons in cortical layer 5A was associated with reduced behavioural responses and ablated the upregulation of 5-HT 4 Rs induced by SSRI treatment, but did not reveal a baseline depression-like phenotype 10 . Thus, the regulation by p11 of mood-related behaviours versus antidepressant responses seems to involve different brain areas.
Molecular and cellular actions of p11 p11 forms a tight non-covalent dimer through its helix I and helix IV (FIG. 3a,c) . p11 was initially discovered as an interacting partner for calcium-dependent lipidbinding protein annexin A2 (REF. 5 ). Helix I, the hinge and the carboxyl terminus of p11 participate in annexin A2 binding. Annexin A2 is a member of the annexin multigene family. The amino-terminal 12 amino acids of annexin A2 that form an amphiphatic α-helix are sufficient for p11 binding (FIG. 3b) . Annexin A2 also has a nuclear export signal motif in the N terminus and four annexin repeat domains. The X-ray crystal structure of p11 in complex with the N-terminal region from annexin A2 showed that the four helices from each monomer are arranged in an antiparallel manner and that the p11 dimer contains two identical annexin A2-binding sites (a hydrophobic cleft formed by the C-terminal region from one monomer and the helix I from the other monomer), forming a heterotetramer 11, 28 ( FIG. 3c) . p11 can be targeted to membranes via complex formation with annexin A2, probably in a calcium-regulated manner because the annexin A2 subunit requires calcium for efficient membrane binding (FIG. 3d) . The interaction was initially observed in yeast two-hybrid screening in which the third intracellular loops of 5-HTRs were used as 'baits' . The precise p11-binding motif in 5-HTRs and the role of annexin A2 in the interaction between p11 and 5-HTRs remain to be studied.
A recent study identified a chromatinremodelling factor, SMARCA3, as a binding protein of the p11-annexin A2 heterotetramer 11 . Other binding partners of the heterotetramer were identified as AHNAK1 and SPT6H (suppressor of Ty 6 homologue (Saccharomyces cerevisiae)) 11 . A p11-binding motif is located in the N terminus of SMARCA3 (REF. 11) (FIG. 3e) . This motif is highly homologous to the p11-binding motif found in the C terminus of AHNAK1 (FIG. 3f) . X-ray crystal structures of p11-annexin A2 in complex with the motif peptides found in SMARCA3 and AHNAK1 revealed that p11 and annexin A2 cooperate to create a unique binding pocket for the SMARCA3 or AHNAK1 motif peptide ( see FIG. 3g for the complex with the SMARCA3 peptide) 11 . The complexes with the SMARCA3 motif peptide and the AHNAK1 motif peptide share very similar intermolecular contacts and recognition principles.
By virtue of these interactions, p11 mediates antidepressant actions both at the plasma membrane and in the nucleus, as described below (FIG. 4) . It is also possible that p11 regulates antidepressant actions by virtue of its interactions with other binding proteins, including the ion channels and enzymes mentioned earlier, but this remains to be studied.
Role of p11 in 5-HT 1B R and 5-HT 4 R function. In mice, p11 is colocalized with 5-HT 1B R and/or 5-HT 4 R in many cell types of the cerebral cortex, hippocampus and nucleus accumbens 3, 9 . The third intracellular loops of 5-HT 1B R and 5-HT 4 . Likewise, radioligand binding to the 5-HT 1B R is increased in the mouse brain after virusmediated overexpression of p11 (REF. 12 ). Conversely, radioligand binding at 5-HT 1B R and 5-HT 4 R is reduced in p11-knockout mice 2, 3 . These data indicate that p11 promotes the cell surface expression of certain 5-HTRs in neurons (FIG. 4) , but the precise mechanisms are yet to be determined.
Experiments in striatal slices demonstrated that both the inhibitory effect of a 5-HT 1B R agonist on the levels of phosphorylated synapsin I (a presynaptic protein that has a role in vesicle docking and neurotransmitter release) and the inhibitory effect of 5-HT on corticostriatal glutamatergic synaptic transmission are dependent on p11 (REF. 2). Moreover, in primary neuronal cultures from the mouse cortex or striatum, p11 potentiated the effects of 5-HT 1B R and 5-HT 4 R activation on calcium influx and ERK1/2 signalling 2, 3, 12 .
Interactions between p11 and 5-HT signalling are bidirectional, as 5-HT is thought to regulate p11 expression 2,14 . 5-HT 1B R and 5-HT 4 R oppositely regulate several intracellular signalling pathways, and it could be assumed that any actions of 5-HT on p11 would be cancelled out if both signalling pathways are activated. However, at least in some brain regions, 5-HT 1B R, 5-HT 1D R and 5-HT 4 R may regulate p11 in distinct, non-overlapping cell types. At the individual cellular level, this may cause opposite effects on p11 regulation, but at the circuitry level, it may lead to additive actions on output function. Such a scenario has been described for dopamine D1 versus D2 receptors in the basal ganglia. D1 and D2 receptors signal oppositely to cAMP but are segregated in striatonigral versus striatopallidal neurons. Through their actions in the direct and indirect pathways of the basal ganglia, the net outcome is a synergistic inhibition of substantia nigra pars reticulata 30 . Further evidence for an interaction between p11 and 5-HTRs has come from behavioural studies in p11-knockout mice. In these mice, the antidepressant-like effects of 5-HT 1B R agonists 31 and 5-HT 4 R agonists 32 , but not of 5-HT 6 R agonists 33 , in the tail suspension test and forced swim test were reduced when compared with wild-type mice 2, 3 . The anxiolytic effects of 5-HT 1B R and 5-HT 4 R agonists on thigmotaxis seen in the open field in wild-type mice were also reduced in p11-knockout mice 2, 3 . These findings suggest that p11, by virtue of its ability to promote accumulation of 5-HTRs at the cell surface, serves as an amplification mechanism for 5-HTR-mediated actions (FIG. 4) . Initial studies also implicate p11 in regulating 5-HT-mediated effects on cognitive processing, which may be relevant to depression and antidepressant responses. Specifically, 5-HT 1B R agonists had opposite effects on emotional learning in the passive avoidance test in wild-type mice and p11-knockout mice, impairing it in the former but enhancing it in the latter 26 . Studies using viral overexpression of p11 in the dentate gyrus and CA1 regions of the hippocampus of p11-knockout mice suggested that the hippocampus mediates the effects of p11 on 5-HT 1B R-mediated emotional learning. These data point to an important role for p11 in tuning 5-HT 1B R-mediated regulation of emotional processing in hippocampus, but the cell types involved in these effects remain to be identified.
Role of p11 in SMARCA3 function. p11 forms a heterotetramer with annexin A2. Levels of both p11 and annexin A2 are upregulated in the hippocampus after chronic SSRI administration in wild-type mice 11 (FIG. 4) as are levels of the heterotetrameric form of p11-annexin A2 (REF. 11 ). In contrast to p11 and annexin A2, the levels of SMARCA3 protein and mRNA were not altered after treatment with an SSRI. However, chronic SSRI administration increased the level of the ternary complex of p11-annexin A2-SMARCA3. Thus, p11 and annexin A2 induction facilitates the assembly of the p11-annexin A2-SMARCA3 complex 11 . SMARCA3 belongs to the family of SWI/SNF proteins that remodel chromatin using energy released through ATP 34 . Transcription factors such as SP1, SP3, EGR1 (early growth response protein 1) and c-REL are known to bind to the C terminus of SMARCA3, which enables their delivery to the relevant gene promoters 34 . By forming a complex with p11-annexin A2, SMARCA3 promotes its own localization to the nuclear matrix fraction 11 , where critical nuclear events, such as gene expression, replication and repair processing, occur 35 . A previous study 36 and findings from our laboratory (Y.K., unpublished observations) indicate that p11 and annexin A2 shuttle between the cytoplasm and nucleus, and that the nuclear export signal located in the N terminus of annexin A2 (FIG. 3b) plays a crucial part in the nuclear export of both p11 and annexin A2. Specifically, annexin A2 has been shown to associate with the nuclear matrix 37 , which is composed of nuclear lamins, actin and actin-related proteins, and phospholipids 35, 38 , and the subnuclear targeting of SMARCA3 is probably controlled by the intrinsic phospholipid-and actin-binding properties of annexin A2 (REF. 29 ). The SMARCA3 interaction with p11-annexin A2 also increases its DNAbinding affinity and transcriptional activity 11 . Like most chromatin remodelling complexes, SMARCA3 displays DNA-and/ or nucleosome-dependent ATPase activity 39, 40 . The enhanced DNA binding leads to SMARCA3 activation, which in turn initiates ATP-dependent chromatin remodelling of target genes and recruitment of transcription factors that are bound to the C-terminal domain of SMARCA3 to the specific locus of the genomic DNA.
Mice with a constitutive absence of SMARCA3 show reduced responses to SSRIs in anhedonia and novelty-suppressed feeding tests 11 , but these mice have no baseline depression-like or anxiety phenotype 11 . Thus, the p11-annexin A2-SMARCA3 complex appears to be an important mediator of antidepressant responses. p11 regulates antidepressant-induced neurogenesis. It has been demonstrated that in the subgranular zone of the hippocampus of both rodents and humans, neurogenesis continues past development into adulthood 41, 42 . This discovery has generated an immense interest in possible functional implications of adult neurogenesis in both normal and pathological states. Interestingly, nearly all types of conventional antidepressant treatments induce adult hippocampal neurogenesis 43, 44 . Some, but not all, reports suggest that adult neurogenesis mediates at least some of the actions of antidepressants. For example, ablation of neurogenesis in mice blocks the behavioural effect of fluoxetine in the noveltysuppressed feeding task 44 . The stimulatory effects of fluoxetine on cell proliferation, neurogenesis, cell survival and apoptosis in the hippocampus are reduced in p11-knockout mice 27 . Similarly, chronic fluoxetineinduced proliferation of neural progenitors is abolished and survival of newborn neurons is partially reduced in constitutive SMARCA3-knockout mice 11 . These findings suggest that the p11-annexin A2-SMARCA3 complex contributes to multiple stages of antidepressant-stimulated neurogenesis. The complex probably acts in a non-cell-autonomous fashion, as p11 expression is increased by chronic fluoxetine in the hippocampus, specifically in GABAergic basket cells and glutamatergic hilar mossy cells in the dentate gyrus (in both of which p11 is colocalized with SMARCA3 (REF. 11)) but not in the newborn cells of this region 11 .
Conclusions and future directions
The findings summarized here suggest an important role for p11 in the pathophysiology of depression and in mediating therapeutic actions of monoamine-based antidepressant regimens. Future studies should examine the possible involvement of p11 in mediating therapeutic responses to other antidepressant approaches, such as deep brain stimulation of the cingulate cortex 45 or treatment with ketamine (a fast-acting antidepressant), and related glutamatergic substances 46 . It is intriguing that viral transduction of p11 to neurons in the nucleus accumbens of constitutive p11-knockout mice abolishes their depression-like Figure 4 | How SSRI antidepressants may regulate interactions between 5-HT receptors, p11, annexin A2 and SMARCA3. Both p11 and annexin A2 mRNA and protein levels are upregulated in the hippocampus and cortex after chronic selective serotonin (5-hydroxytryptamine (5-HT)) reuptake inhibitor (SSRI) administration, and this upregulation is likely to be mediated by 5-HT receptors (5-HTRs). p11 in turn increases 5-HTR levels at the plasma membrane, providing an amplification mechanism for antidepressant actions. The heterotetrameric p11-annexin A2 complex binds to SWI/ SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3 (SMARCA3) and is then targeted to the nuclear matrix, where it remodels chromatin and regulates gene transcription. This regulation appears to underlie increased hippocampal neurogenesis and antidepressant behavioural responses observed after chronic SSRI treatment. Both p11-knockout mice and SMARCA3-knockout mice exhibit reduced neurogenic and behavioural responsiveness to SSRI administration. The question mark indicates that the possible role of neurogenesis in behavioural improvement has not been rigorously demonstrated.
phenotype in several tests, including sucrose consumption, which is often referred to as an index of hedonic drive 8, 12 . Ongoing studies in non-human primates are being carried out to determine whether gene transfer aimed at overexpressing p11 in the nucleus accumbens is safe and might serve as a therapy for depressed individuals. Studies in cell type-specific p11-knockout mice have defined distinct cell types in which p11 is implicated in depression-like states and in therapeutic responses to antidepressants. Further studies of these mouse lines, combined with optogenetic, viral and/or tracing approaches, should shed light on the brain circuitries that are perturbed in depression. p11 is expressed in peripheral blood cells, and ongoing work should establish whether peripheral p11 expression can serve as a biomarker of depression and/or responsiveness to antidepressant treatment. Two relatively small studies in humans have failed to find any association between polymorphisms of the P11 gene and depression 47, 48 . However, given the difficulties in finding a reproducible and robust association between singlenucleotide polymorphisms and depression 49 , more detailed studies are probably necessary to determine whether polymorphisms in the P11 gene are associated with subgroups of patients with depression or treatment responsiveness.
From a mechanistic standpoint, more detailed studies on the regulation of 5-HTR trafficking by p11 and annexin A2 may reveal valuable and novel therapeutic targets. It will also be important to identify the genes activated by the p11-annexin A2-SMARCA3 chromatin remodelling complex and to determine which of these are involved in mediating therapeutic responses to antidepressants.
Finally, we recently examined a large clinical dataset collected to assess antidepressant efficacy (the STAR*D trial) and found that depressed individuals who reported taking NSAIDs while on an SSRI (citalopram) had a lower remission rate than those who did not report NSAID use 19 . This finding offers a possible explanation for why a considerable number of patients with depression do not respond to SSRIs. It should be noted that other classes of antidepressants are not negatively affected by anti-inflammatory treatments, offering a possible treatment alternative for these patients. It would be interesting to study how antidepressants, depression-like states and stress regulate proversus anti-inflammatory cytokine levels and to correlate these results with regulation of p11 and behaviour.
